MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, led by Sam Possemiers, Katja Conrath, and Grégoire Franoux, has announced a €55 million Series B financing round led by French pharmaceutical group Biocodex and included strong participation from German-based ATHOS, as well as new investor BNP Paribas Fortis Private Equity and existing investors SFPIM, Ackermans & van Haaren (AvH), OMX Europe Venture Fund (OMX), Qbic II, and VIB. As part of the Series B financing, Jean-Patrick Hennebelle (Biocodex), Julian Zachmann (ATHOS), and Goedele Ertveldt (SFPIM) will join MRM Health’s Board of Directors.

MRM Health will use the funding to complete a Phase 2b trial of MH002 for ulcerative colitis, advance two novel microbial consortia programs to IND approval targeting inflammation and immune-oncology, and expand its LBP portfolio through strategic partnerships in human and animal health.

MRM Health and Biocodex plan a strategic collaboration to develop new therapeutic assets and scalable LBP manufacturing, providing significant non-dilutive funding to strengthen MRM Health’s operations.